Oncology Brothers: Practice-Changing Cancer Discussions
Oncology Brothers
The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and advanced practice providers (APPs) involved in the care of cancer patients.Drs. Rahul and Rohit Gosain, both esteemed oncologists, bring a wealth of experience and expertise from their general community practice to these discussions. Through short and engaging interviews with world-renowned researchers, clinicians, hematologists, and oncologists, they present practice-changing data in a concise, bite-sized format. Get the latest FDA approvals news, oncology conference highlights, and treatment algorithms in 25 minutes or less. Conversations center around common cancers you see in your clinic like breast cancer, prostate cancer, kidney cancer, bladder cancer, lung cancer, and GI cancers. With new indications and approvals, we talk about how to incorporate this data in your day to day clinical practice. Each episode includes visual presentations so you can follow along within the podcast players and on YouTube @oncbrothers. These visual tools and algorithms will provide an outline on what is covered in each episode. Immediately apply the latest insights and advancements in your daily practice, ensuring the delivery of optimal cancer care to patients within your local communities.If you want to navigate the complexities of your hematology & oncology practice and stay current, the Oncology Brothers Podcast offers invaluable insights and practical takeaways to enhance your professional journey and improve patient outcomes. For more information, please visit: www.oncbrothers.com, and connect with us on Twitter/X/Instagram/TikTok: @oncbrothers, or email us at info@oncbrothers.com
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
Privacy Policy: https://oncbrothers.com/privacy-policy
Terms & Conditions: https://oncbrothers.com/terms-and-conditions
Episodes
Mentioned books
Sep 18, 2025 • 24min
WCLC 2025 Highlights: FLAURA2, HARMONi, ALCHEMIST with Dr. Balazs Halmos
Dr. Balazs Halmos, a thoracic medical oncologist at Montefiore Einstein Cancer Center, joins the discussion on crucial findings from the World Conference on Lung Cancer 2025. He highlights the FLAURA2 trial, showcasing how osimertinib combined with chemotherapy enhances survival for EGFR-positive non-small cell lung cancer patients. Halmos delves into the HARMONi trial's unexpected results with a bi-specific antibody and the significance of ctDNA. He wraps up with insights on crizotinib's role in ALK-positive cases and the evolving landscape of precision oncology.
17 snips
Sep 11, 2025 • 25min
Treating and Managing Chronic Lymphocytic Leukemia (CLL) in 2025: Dr. Mazyar Shadman
Dr. Mazyar Shadman, a leading expert in lymphoid malignancies at Fred Hutch Cancer Center, discusses the future of Chronic Lymphocytic Leukemia (CLL) treatment. He emphasizes the importance of shared decision-making and explores the timing for initiating treatment. Key topics include the choice between time-limited venetoclax regimens and continuous BTK inhibitors, the significance of minimal residual disease (MRD), and innovative strategies for managing relapsed CLL, such as Pirtobrutinib and CAR-T therapies.
Aug 29, 2025 • 15min
Managing Side Effects of New Treatments for Small Cell Lung Cancer
Dr. Misty Shields, a medical oncologist at Indiana University specializing in small cell lung cancer, shares her insights on managing side effects from new treatments. She discusses the latest advancements from ASCO 2025, focusing on the treatment algorithm for patients with good performance status. Key points include common side effects of lurbinectedin and immunotherapy, strategies for managing hematologic toxicities, and the crucial role of supportive and palliative care in improving patient quality of life. Collaboration between community oncologists and academic centers is emphasized for optimal care.
Aug 25, 2025 • 13min
FDA Approval of Zongertinib for HER2 Mutated Non-Small Cell Lung Cancer (NSCLC) - Dr. Joshua Sabari
Dr. Joshua Sabari, a medical oncologist at NYU Langone Cancer Center, shares his expertise on the groundbreaking approval of Zongertinib for HER2-mutated non-small cell lung cancer. He discusses the prevalence of HER2 mutations, revealing key study findings with impressive response rates and progression-free survival data. The podcast dives into the management of side effects, particularly diarrhea, and compares Zongertinib with trastuzumab deruxtecan in treatment settings. Dr. Sabari also explores future directions for HER2-targeted therapies.
Aug 21, 2025 • 16min
Latest Clinical Data for First-line Maintenance and R/R Small-Cell Lung Cancer (SCLC)
Welcome to the Oncology Brothers podcast! In this episode, we kick off a three-part CME series focused on small cell lung cancer (SCLC). Joined by Dr. Hossein Borghaei, Chief of Thoracic Oncology at the Fox Chase Cancer Center. Together they dived into the evolving treatment landscape for SCLC, highlighting recent advancements and data from ASCO 2025.
Episode Highlights:
• Overview of the current standard of care for limited and extensive-stage SCLC.
• Discussion on the role of concurrent chemoradiation therapy and the new standard of care involving immunotherapy.
• Insights into the use of lurbinectedin in maintenance therapy and its impact on overall survival.
• Exploration of the promising results from the DeLLphi study on tarlatamab, a bispecific antibody, and its implications for treatment.
• The importance of patient selection and managing side effects in treatment decisions.
Join us as we navigate the complexities of SCLC treatment and look forward to future advancements that may improve patient outcomes.
Accreditation/Credit Designation
Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.
Link to gain CME credits from this activity:
https://www.gotoper.com/courses/breaking-down-the-latest-clinical-data-for-first-line-maintenance-and-rr-sclc
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
#OncologyBrothers #SmallCellLungCancer #CME #ASCO2025 #LungCancer #Immunotherapy #CancerTreatment
Aug 18, 2025 • 22min
FDA Approval of Datopotamab deruxtecan (Dato-DXd) in EGFR Mutated Lung Cancer - Dr. Jacob Sands
In this episode of the Oncology Brothers podcast, Drs. Rohit & Rahul Gosain welcome Dr. Jacob Sands, a thoracic medical oncologist from the Dana-Farber Cancer Institute, to discuss the recent FDA approval of Dato-DXD (datopotamab deruxtecan) for previously treated EGFR-mutated non-small cell lung cancer (NSCLC).
Key Topics:
• Overview of Dato-DXd and its FDA approval
• Mechanism of action and study design of the TROPION Lung trials
• Efficacy and safety profile of Dato-DXd
• Management of side effects and clinical pearls
• Treatment sequencing for EGFR-mutated NSCLC
Join us as we dive into the details of the TROPION Lung trials that led to this significant approval, the mechanism of action of Dato-DXd, and the implications for patients with various EGFR mutations.
Dr. Sands shared insights on the study design, efficacy, and tolerability of this new antibody-drug conjugate, as well as important clinical pearls for managing side effects such as stomatitis, dry eyes, and interstitial lung disease (ILD).
We also explored the current treatment landscape for EGFR-mutated NSCLC, including the sequencing of therapies and the potential role of Dato-DXd in clinical practice.
Tune in for an informative discussion that highlights the exciting advancements in oncology and the hope they bring to patients.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more insights into the world of oncology!
Aug 11, 2025 • 18min
Diagnosis and Treatment of Myelofibrosis with Dr. Raajit Rampal: Testing, Treatment, Supportive care
Welcome to the Oncology Brothers podcast! In this episode, we continue our hematology series by diving deep into myelofibrosis (MF) with Dr. Raajit Rampal, an expert in myeloproliferative neoplasms from the Memorial Sloan Kettering Cancer Center.
Join Drs. Rahul and Rohit Gosain as they discuss the latest updates in symptom management, emerging treatment combinations, and the importance of timely diagnosis and risk stratification for patients presenting with cytopenias and splenomegaly.
Key topics covered in this episode include:
• The initial workup and diagnostic criteria for myelofibrosis
• The role of next-generation sequencing and bone marrow biopsy
• Risk stratification using the IPSS and DIPSS scoring systems
• First-line treatment options, including the four available JAK inhibitors: Ruxolitinib, Momelotinib, Fedratinib, and Pacritinib
• Supportive care strategies for managing anemia and thrombocytopenia
• The importance of clinical trials and early referral for transplant
Tune in to gain valuable insights into the evolving treatment landscape for myelofibrosis and learn how community oncologists can effectively manage this complex disease.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to subscribe for more episodes in our hematology series and check out our previous discussions!
Aug 7, 2025 • 19min
Managing Toxicities of TKIs and HIF-2 inhibitor in Renal Cell Carcinoma (RCC)
In this insightful discussion, Dr. Monty Pal, a medical oncologist from City of Hope, shares his expertise on renal cell carcinoma treatment. He dives into the nuances of managing toxicities from tyrosine kinase inhibitors (TKIs) and HIF-2 alpha inhibitors, offering practical dosing strategies. The conversation highlights common side effects like hypertension and fatigue, and Dr. Pal provides invaluable clinical pearls for mitigating these issues while maintaining patients' quality of life. Discover effective management techniques for both first- and second-line therapies!
Aug 4, 2025 • 26min
Myeloproliferative Neoplasms (MPN) Treatment: Polycythema Vera (PV) & Essential Thrombocythemia (ET)
Dr. Andrew Kuykendall, a hematologist from Moffitt Cancer Center, brings his expertise in myeloproliferative neoplasms to a discussion centered on polycythemia vera (PV) and essential thrombocythemia (ET). Key topics include the vital role of JAK2 mutation testing in diagnosis and the latest treatments like ruxolitinib and resveratide. Dr. Kuykendall also emphasizes risk stratification for ET and the importance of managing acquired von Willebrand disease in patients with high platelet counts, showcasing a new era in personalized cancer care.
Jul 31, 2025 • 11min
Latest Advances in Tumor-Agnostic Strategies for NTRK Fusion-Positive Cancer
Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain, practicing community oncologists, share their key takeaways from a session on NTRK Fusion Positive Solid Malignancies, they moderated during a satellite event at ASCO 2025 in partnership with Medscape Global Oncology.
Join us as we discuss:
• The prevalence of NTRK fusions in various cancers and why community oncologists should be aware of them.
• The importance of comprehensive next-generation sequencing (NGS) for detecting these fusions across diverse histologies.
• Available treatment options, including first-generation NTRK inhibitors like larotrectinib and entrectinib, and their efficacy in improving overall and progression-free survival.
• Insights into the CNS activity of these treatments and the common side effects patients may experience.
• Special considerations for pediatric patients, including formulation challenges and the potential for re-challenging with NTRK inhibitors.
Don't forget to check out the full accredited enduring program by Medscape Global Oncology linked below, and earn your CME credit.
https://www.medscape.org/viewarticle/1002679?src=acdmpart_onc-brothers_1002679
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
#entrectinib #larotrectinib #repotrectinib
